Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pegylated Liposomal Doxorubicin+ SL-172154 · 1 trial · 7 indications
Number of participants with treatment emergent adverse events from dose escalation and expansion cohorts
Based on review of all data, including safety, tolerability, PK, antitumor activity, and PD effects"
| Arm | Type | Description |
|---|---|---|
| Pegylated Liposomal Doxorubicin + SL-172154 (SIRPα-Fc-CD40L) | EXPERIMENTAL | Pegylated Liposomal Doxorubicin (PLD) will be administered via intravenous administration + SL-172154 (SIRPα-Fc-CD40L) will be administered via intravenous administration. |
| Mirvetuximab + SL-172154 (SIRPα-Fc-CD40L) | EXPERIMENTAL | Mirvetuximab (MIRV) will be administered via intravenous administration + SL-172154 (SIRPα-Fc-CD40L) will be administered via intravenous administration |
| Name | Type | Description |
|---|---|---|
| Pegylated Liposomal Doxorubicin + SL-172154 | DRUG | The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc. |
| Mirvetuximab + SL-172154 | DRUG | The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc. |
Inclusion Criteria: 1. Subject has voluntarily agreed to participate by giving written informed consent in accordance with ICH/GCP guidelines and applicable local regulations. 2. Age ≥18 years 3. \[PLD Cohort\] Subject has a histologically confirmed diagnosis of high grade epithelial ovarian cancer...
Pegylated Liposomal Doxorubicin+ SL-172154 is being studied for the treatment of platinum-resistant ovarian cancer, including fallopian tube cancer and primary peritoneal carcinoma. It is an investigational combination therapy evaluated in a Phase 1 clinical trial for patients with these conditions.
Pegylated Liposomal Doxorubicin+ SL-172154 is being developed by Shattuck Labs, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol STTK. The company is conducting clinical research on this combination therapy for platinum-resistant ovarian cancer.
Pegylated Liposomal Doxorubicin+ SL-172154 is in Phase 1 clinical development. The Phase 1b study has been completed, and the therapy remains investigational, meaning it has not been approved by regulatory authorities and is still undergoing clinical evaluation.
Pegylated Liposomal Doxorubicin+ SL-172154 was studied in clinical trial NCT05483933, a Phase 1b study of SL-172154 administered with combination agents in subjects with ovarian cancers. The trial enrolled 86 female participants aged 18 years and older and was conducted in the United States, Canada, Spain, and the United Kingdom.
Pegylated Liposomal Doxorubicin+ SL-172154 is a combination therapy that includes SL-172154, an investigational agent developed by Shattuck Labs. The clinical trial NCT05483933 specifically studied SL-172154 administered with combination agents, including pegylated liposomal doxorubicin, in patients with platinum-resistant ovarian cancer.